NR2E1
MOLECULAR TARGETnuclear receptor subfamily 2 group E member 1
NR2E1 (nuclear receptor subfamily 2 group E member 1) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NR2E1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | propafenone | 4.53 | 92 |
| 2 | tadalafil | 3.93 | 50 |
| 3 | levopropranolol | 2.94 | 18 |
| 4 | tryptoline | 2.71 | 14 |
| 5 | dexpropranolol | 2.48 | 11 |
| 6 | retinal | 1.95 | 6 |
| 7 | Caffeine | 0.69 | 1 |
| 8 | Propranolol | 0.69 | 1 |
| 9 | Retinaldehyde | 0.69 | 1 |
About NR2E1 as a Drug Target
NR2E1 (nuclear receptor subfamily 2 group E member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented NR2E1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NR2E1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.